Trial Profile
Second of two planned phase III pivotal trials of autologous cell therapy utilising tumour infiltrating lymphocytes [Contego] as second-line therapy in patients with stage IV metastatic melanoma.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2013
Price :
$35
*
At a glance
- Drugs Lifileucel (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- 13 Oct 2011 New trial record